To further forecast the immunotherapeutic efficacy of risk score, two subtypes of IPS values (IPS-PD-1/PD-L1/PD-L2 positive and IPS-CTLA-4 positive) were employed as the surrogates of the HCC patients’ responses to immunotherapy. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.